Novel	O
region	O
within	O
the	O
V	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
responsible	O
for	O
tissue	O
and	O
stage-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
in	O
human	B-cell_type
lymphoid	I-cell_type
neoplasms	I-cell_type
.	O

Immunoglobulin	B-protein
gene-specific	I-protein
transacting	I-protein
factors	I-protein
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
lymphoid	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

The	O
role	O
of	O
these	O
factors	O
in	O
B-cell	B-cell_type
differentiation	O
and	O
stage-specific	O
expression	O
of	O
these	O
genes	O
is	O
,	O
however	O
,	O
not	O
fully	O
understood	O
.	O

We	O
have	O
used	O
a	O
model	O
of	O
human	O
lymphoid	O
neoplasia	O
to	O
address	O
this	O
question	O
.	O

Different	O
fragments	O
of	O
unrearranged	B-DNA
human	I-DNA
variable	I-DNA
region	I-DNA
of	O
immunoglobulin	B-DNA
kappa	I-DNA
gene	I-DNA
(	O
V	B-DNA
kappa	I-DNA
)	O
were	O
used	O
for	O
cell-free	O
in	O
vitro	O
transcription	O
and	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Previously	O
described	O
enhancement	O
of	O
in	O
vitro	O
transcription	O
that	O
was	O
only	O
seen	O
with	O
nuclear	O
extracts	O
derived	O
from	O
B-cell	B-cell_type
neoplasms	I-cell_type
corresponding	O
to	O
the	O
late	O
stages	O
of	O
B-cell	B-cell_type
differentiation	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
actions	O
of	O
these	O
factor	O
(	O
s	O
)	O
on	O
the	O
DNA	O
region	O
within	O
the	O
V	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

This	O
region	O
is	O
located	O
within	O
the	O
920	O
bp	O
fragment	O
located	O
210	O
bp	O
upstream	O
from	O
the	O
coding	O
region	O
and	O
this	O
fragment	O
represents	O
a	O
possible	O
novel	O
DNA	O
region	O
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
stage-	O
and	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

Immunology	NULL
1989	NULL
66	NULL
328-334	NULL
Novel	NULL
region	NULL
within	NULL
the	NULL
V	NULL
,	NULL
,	NULL
gene	NULL
promoter	NULL
is	NULL
responsible	NULL
for	NULL
tissue	NULL
and	NULL
stage-specific	NULL
expression	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
in	NULL
human	NULL
lymphoid	NULL
neoplasms	NULL
A.	NULL
E.	NULL
KOSSAKOWSKA	NULL
&	NULL
S.	NULL
J.	NULL
URBANSKI	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Calgary/Foothills	NULL
Hospital	NULL
,	NULL
Calgary	NULL
,	NULL
Alberta	NULL
,	NULL
Canada	NULL
Accepted	NULL
for	NULL
publication	NULL
1	NULL
November	NULL
1988	NULL
SUMMARY	NULL
Immunoglobulin	NULL
gene-specific	NULL
transacting	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
lymphoid	NULL
tissue-specific	NULL
expression	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

The	NULL
role	NULL
of	NULL
these	NULL
factors	NULL
in	NULL
B-cell	NULL
differentiation	NULL
and	NULL
stage-specific	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
is	NULL
,	NULL
however	NULL
,	NULL
not	NULL
fully	NULL
understood	NULL
.	NULL

We	NULL
have	NULL
used	NULL
a	NULL
model	NULL
of	NULL
human	NULL
lymphoid	NULL
neoplasia	NULL
to	NULL
address	NULL
this	NULL
question	NULL
.	NULL

Different	NULL
fragments	NULL
of	NULL
unrearranged	NULL
human	NULL
variable	NULL
region	NULL
of	NULL
immunoglobulin	NULL
kappa	NULL
gene	NULL
(	NULL
V	NULL
,	NULL
)	NULL
were	NULL
used	NULL
for	NULL
cell-free	NULL
in	NULL
vitro	NULL
transcription	NULL
and	NULL
DNA	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

Previously	NULL
described	NULL
enhancement	NULL
of	NULL
in	NULL
vitro	NULL
transcription	NULL
that	NULL
was	NULL
only	NULL
seen	NULL
with	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
B-cell	NULL
neoplasms	NULL
corresponding	NULL
to	NULL
the	NULL
late	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
the	NULL
actions	NULL
of	NULL
these	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
on	NULL
the	NULL
DNA	NULL
region	NULL
within	NULL
the	NULL
V	NULL
,	NULL
gene	NULL
promoter	NULL
.	NULL

This	NULL
region	NULL
is	NULL
located	NULL
within	NULL
the	NULL
920	NULL
bp	NULL
fragment	NULL
located	NULL
210	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
coding	NULL
region	NULL
and	NULL
this	NULL
fragment	NULL
represents	NULL
a	NULL
possible	NULL
novel	NULL
DNA	NULL
region	NULL
,	NULL
which	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
stage-	NULL
and	NULL
tissue-specific	NULL
expression	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

INTRODUCTION	NULL
Lymphoid	NULL
tissue-specific	NULL
expression	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
both	NULL
the	NULL
enhancer	NULL
(	NULL
Ephrussi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Mercola	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
as	NULL
well	NULL
as	NULL
promoter	NULL
(	NULL
Gopal	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
sequences	NULL
.	NULL

Several	NULL
different	NULL
protein	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
at	NULL
specific	NULL
DNA	NULL
binding	NULL
sites	NULL
on	NULL
the	NULL
immunoglobulin	NULL
genes	NULL
(	NULL
Weinberger	NULL
,	NULL
Baltimore	NULL
&	NULL
Sharp	NULL
,	NULL
1986	NULL
;	NULL
Sen	NULL
&	NULL
Baltimore	NULL
,	NULL
1986b	NULL
;	NULL
Mocikat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Landolfi	NULL
,	NULL
Capra	NULL
&	NULL
Tucker	NULL
,	NULL
1986	NULL
;	NULL
Gimble	NULL
,	NULL
Levens	NULL
&	NULL
Max	NULL
,	NULL
1987	NULL
)	NULL
,	NULL
assayed	NULL
by	NULL
in	NULL
vitro	NULL
binding	NULL
.	NULL

An	NULL
octamer	NULL
sequence	NULL
located	NULL
upstream	NULL
of	NULL
TATA	NULL
motif	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
sufficient	NULL
for	NULL
lymphoid-specific	NULL
promoter	NULL
activity	NULL
(	NULL
Wirth	NULL
,	NULL
Staudt	NULL
&	NULL
Baltimore	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
factors	NULL
described	NULL
,	NULL
however	NULL
,	NULL
are	NULL
ubiquitous	NULL
(	NULL
Weinberger	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Mocikat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
and	NULL
sequences	NULL
in	NULL
immunoglobulin	NULL
gene	NULL
promoter/enhancer	NULL
elements	NULL
which	NULL
bind	NULL
these	NULL
proteins	NULL
were	NULL
also	NULL
discovered	NULL
in	NULL
other	NULL
eukaryotic	NULL
and	NULL
prokaryotic	NULL
genes	NULL
(	NULL
Falkner	NULL
,	NULL
Mocikat	NULL
&	NULL
Zachau	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

Purification	NULL
of	NULL
the	NULL
highly	NULL
conserved	NULL
octamer	NULL
sequence-binding	NULL
protein	NULL
from	NULL
human	NULL
B	NULL
cells	NULL
has	NULL
been	NULL
achieved	NULL
by	NULL
sequence-specific	NULL
DNA	NULL
affinity	NULL
Abbreviations	NULL
:	NULL
V	NULL
,	NULL
,	NULL
variable	NULL
region	NULL
of	NULL
human	NULL
kappa	NULL
light	NULL
chain	NULL
immunoglobulin	NULL
gene	NULL
;	NULL
ATP	NULL
,	NULL
adenosine	NULL
5'-triphosphate	NULL
;	NULL
CTP	NULL
,	NULL
cytosine	NULL
5'-triphosphate	NULL
;	NULL
FCS	NULL
,	NULL
fetal	NULL
calf	NULL
serum	NULL
;	NULL
GTP	NULL
,	NULL
guanosine	NULL
5'-triphosphate	NULL
;	NULL
MEM	NULL
,	NULL
minimal	NULL
essential	NULL
medium	NULL
;	NULL
TE	NULL
,	NULL
Tris-EDTA	NULL
;	NULL
UTP	NULL
,	NULL
uridine	NULL
5-triphosphate	NULL
.	NULL

Correspondence	NULL
:	NULL
Dr	NULL
A.	NULL
E.	NULL
Kossakowska	NULL
,	NULL
Dept	NULL
.	NULL

of	NULL
Histopathology	NULL
,	NULL
Foothills	NULL
Hospital	NULL
,	NULL
1403-29	NULL
Street	NULL
NW	NULL
.	NULL

,	NULL
Calgary	NULL
,	NULL
Alberta	NULL
,	NULL
Canada	NULL
TN	NULL
219	NULL
.	NULL

328	NULL
chromatography	NULL
(	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

This	NULL
protein	NULL
was	NULL
found	NULL
only	NULL
,	NULL
however	NULL
,	NULL
in	NULL
cells	NULL
of	NULL
B-cell	NULL
origin	NULL
and	NULL
some	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
cells	NULL
of	NULL
non-lymphoid	NULL
lineage	NULL
(	NULL
Staudt	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

DNase	NULL
I	NULL
hypersensitive	NULL
sites	NULL
discovered	NULL
in	NULL
kappa	NULL
genes	NULL
from	NULL
nuclei	NULL
of	NULL
cells	NULL
producing	NULL
kappa	NULL
immunoglobulin	NULL
chains	NULL
correlate	NULL
with	NULL
only	NULL
some	NULL
of	NULL
the	NULL
previously	NULL
described	NULL
putative	NULL
regulatory	NULL
sequences	NULL
(	NULL
Pospelov	NULL
,	NULL
Klobeck	NULL
&	NULL
Zachau	NULL
,	NULL
1984	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
assays	NULL
have	NULL
been	NULL
employed	NULL
to	NULL
establish	NULL
the	NULL
functional	NULL
significance	NULL
of	NULL
the	NULL
transacting	NULL
factors	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
transcription	NULL
of	NULL
kappa	NULL
light	NULL
chain	NULL
gene	NULL
is	NULL
more	NULL
efficient	NULL
in	NULL
B-cell	NULL
than	NULL
HeLa	NULL
extracts	NULL
,	NULL
the	NULL
phenomenon	NULL
dependent	NULL
on	NULL
promoter	NULL
sequences	NULL
(	NULL
Mizushima-Sugano	NULL
&	NULL
Roeder	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
stimulates	NULL
in	NULL
vitro	NULL
transcription	NULL
from	NULL
Adenovirus-2	NULL
major	NULL
late	NULL
promoter	NULL
in	NULL
extracts	NULL
derived	NULL
from	NULL
B	NULL
but	NULL
not	NULL
HeLa	NULL
cells	NULL
(	NULL
Augerau	NULL
&	NULL
Chambon	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

Cell-specific	NULL
transcriptional	NULL
enhancement	NULL
in	NULL
vitro	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
enhancer	NULL
sequence	NULL
of	NULL
IgCu	NULL
,	NULL
demonstrated	NULL
with	NULL
the	NULL
use	NULL
of	NULL
B-cell	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
T-cell	NULL
extracts	NULL
,	NULL
but	NULL
not	NULL
HeLa	NULL
cell	NULL
extracts	NULL
(	NULL
Scholer	NULL
&	NULL
Gruss	NULL
,	NULL
1985	NULL
)	NULL
.	NULL

The	NULL
IgH	NULL
enhancer	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
contain	NULL
binding	NULL
sites	NULL
for	NULL
both	NULL
positive	NULL
and	NULL
negative	NULL
regulatory	NULL
factors	NULL
,	NULL
assayed	NULL
by	NULL
in	NULL
vitro	NULL
transcription	NULL
from	NULL
a	NULL
heterologous	NULL
promoter	NULL
and	NULL
by	NULL
DNase	NULL
I	NULL
footprinting	NULL
and	NULL
DMS-methylation	NULL
protection	NULL
(	NULL
Augereau	NULL
&	NULL
Chambon	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
different	NULL
mechanisms	NULL
of	NULL
regulation	NULL
operate	NULL
at	NULL
different	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
(	NULL
Sen	NULL
&	NULL
Baltimore	NULL
,	NULL
1986a	NULL
,	NULL
Hromas	NULL
&	NULL
Van	NULL
Ness	NULL
,	NULL
1986	NULL
)	NULL
and	NULL
negative	NULL
regulation	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
(	NULL
Scholer	NULL
&	NULL
Gruss	NULL
,	NULL
1985	NULL
;	NULL
Wall	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
has	NULL
been	NULL
described	NULL
.	NULL

It	NULL
Novel	NULL
gene	NULL
promoter	NULL
region	NULL
329	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
promoter	NULL
sequences	NULL
may	NULL
act	NULL
independently	NULL
of	NULL
enhancer	NULL
sequences	NULL
in	NULL
conferring	NULL
tissue	NULL
specificity	NULL
from	NULL
a	NULL
heterologous	NULL
promoter	NULL
(	NULL
Doyen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

It	NULL
is	NULL
apparent	NULL
from	NULL
the	NULL
existing	NULL
data	NULL
that	NULL
tissue-	NULL
and	NULL
stage-specific	NULL
expression	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
comes	NULL
under	NULL
the	NULL
control	NULL
of	NULL
both	NULL
general	NULL
and	NULL
gene-specific	NULL
transcriptional	NULL
factors	NULL
.	NULL

It	NULL
is	NULL
,	NULL
therefore	NULL
,	NULL
necessary	NULL
to	NULL
establish	NULL
a	NULL
functional	NULL
significance	NULL
of	NULL
these	NULL
various	NULL
factors	NULL
in	NULL
models	NULL
that	NULL
simulate	NULL
normal	NULL
B-cell	NULL
differentiation	NULL
.	NULL

Human	NULL
lymphoid	NULL
neoplasia	NULL
is	NULL
ideal	NULL
for	NULL
such	NULL
a	NULL
study	NULL
.	NULL

It	NULL
is	NULL
believed	NULL
that	NULL
these	NULL
neoplasms	NULL
represent	NULL
clones	NULL
of	NULL
cells	NULL
arrested	NULL
at	NULL
various	NULL
stages	NULL
of	NULL
lymphocyte	NULL
differentiation	NULL
(	NULL
Lukes	NULL
&	NULL
Collins	NULL
,	NULL
1974	NULL
;	NULL
Foon	NULL
,	NULL
Schroff	NULL
&	NULL
Gale	NULL
,	NULL
1982	NULL
;	NULL
Godal	NULL
&	NULL
Funderud	NULL
,	NULL
1982	NULL
;	NULL
Nilsson	NULL
and	NULL
Klein	NULL
,	NULL
1982	NULL
,	NULL
Mather	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
.	NULL

These	NULL
different	NULL
classes	NULL
produce	NULL
different	NULL
types	NULL
and	NULL
different	NULL
amounts	NULL
of	NULL
immunoglobulins	NULL
(	NULL
Godal	NULL
and	NULL
Funderud	NULL
,	NULL
1982	NULL
,	NULL
Nilsson	NULL
&	NULL
Klein	NULL
,	NULL
1982	NULL
;	NULL
Mather	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Kelley	NULL
&	NULL
Perry	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

We	NULL
have	NULL
chosen	NULL
this	NULL
model	NULL
of	NULL
human	NULL
lymphoid	NULL
neoplasia	NULL
to	NULL
study	NULL
the	NULL
functional	NULL
significance	NULL
and	NULL
to	NULL
characterize	NULL
the	NULL
immunoglobulin	NULL
gene-specific	NULL
transcription	NULL
factors	NULL
.	NULL

We	NULL
have	NULL
employed	NULL
an	NULL
in	NULL
vitro	NULL
cell-free	NULL
transcription	NULL
assay	NULL
to	NULL
test	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
human	NULL
lymphoid	NULL
neoplasms	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
functionally	NULL
significant	NULL
immunoglobulin	NULL
gene-specific	NULL
transacting	NULL
factors	NULL
(	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
various	NULL
lymphoid	NULL
and	NULL
non-lymphoid	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
from	NULL
fresh	NULL
specimens	NULL
of	NULL
human	NULL
lymphomas	NULL
and	NULL
carcinomas	NULL
were	NULL
preincubated	NULL
with	NULL
V	NULL
,	NULL
gene	NULL
,	NULL
and	NULL
specific	NULL
enhancement	NULL
of	NULL
transcription	NULL
was	NULL
only	NULL
obtained	NULL
with	NULL
the	NULL
use	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
neoplastic	NULL
lymphoid	NULL
B	NULL
cells	NULL
that	NULL
produce	NULL
large	NULL
amounts	NULL
of	NULL
immunoglobulins	NULL
and	NULL
correspond	NULL
to	NULL
late	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
(	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
have	NULL
tested	NULL
different	NULL
subclones	NULL
of	NULL
the	NULL
same	NULL
V	NULL
,	NULL
gene	NULL
with	NULL
the	NULL
use	NULL
of	NULL
in	NULL
vitro	NULL
transcription	NULL
and	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
in	NULL
order	NULL
to	NULL
localize	NULL
the	NULL
DNA	NULL
region	NULL
(	NULL
s	NULL
)	NULL
responsible	NULL
for	NULL
the	NULL
action	NULL
of	NULL
the	NULL
previously	NULL
described	NULL
transacting	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
(	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
and	NULL
fresh	NULL
specimens	NULL
All	NULL
lymphoid	NULL
cell	NULL
lines	NULL
were	NULL
grown	NULL
in	NULL
suspension	NULL
culture	NULL
in	NULL
MEM	NULL
a-medium	NULL
,	NULL
supplemented	NULL
with	NULL
20	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
.	NULL

$	NULL
3a	NULL
HeLa	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
suspension	NULL
culture	NULL
in	NULL
MEM	NULL
a-medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Surgical	NULL
specimens	NULL
were	NULL
obtained	NULL
in	NULL
the	NULL
Department	NULL
of	NULL
Pathology	NULL
and	NULL
processed	NULL
immediately	NULL
.	NULL

Nuclear	NULL
extracts	NULL
Nuclear	NULL
extracts	NULL
from	NULL
cultured	NULL
cells	NULL
and	NULL
from	NULL
single	NULL
cell	NULL
suspensions	NULL
,	NULL
obtained	NULL
from	NULL
fresh	NULL
surgical	NULL
specimens	NULL
,	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
the	NULL
methodology	NULL
described	NULL
by	NULL
Bazett-Jones	NULL
,	NULL
Yeckel	NULL
&	NULL
Gottesfeld	NULL
(	NULL
1985	NULL
)	NULL
.	NULL

These	NULL
extracts	NULL
were	NULL
ali-quoted	NULL
and	NULL
kept	NULL
frozen	NULL
at	NULL
-70°	NULL
.	NULL

DNA	NULL
templates	NULL
HK101/3	NULL
clone	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
D.	NULL
L.	NULL
Bentley	NULL
(	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
)	NULL
(	NULL
Bentley	NULL
,	NULL
Farrell	NULL
&	NULL
Rabbits	NULL
,	NULL
1982	NULL
)	NULL
,	NULL
and	NULL
the	NULL
HK	NULL
101/80	NULL
clone	NULL
represents	NULL
a	NULL
558	NULL
bp	NULL
Pst	NULL
1	NULL
fragment	NULL
subcloned	NULL
in	NULL
pTZ-19R	NULL
(	NULL
Pharmacia	NULL
)	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

These	NULL
templates	NULL
were	NULL
used	NULL
for	NULL
in	NULL
vitro	NULL
run-off	NULL
transcription	NULL
assay	NULL
after	NULL
digestion	NULL
with	NULL
appropriate	NULL
restriction	NULL
endonucleases	NULL
;	NULL
920	NULL
bp	NULL
,	NULL
558	NULL
bp	NULL
,	NULL
and	NULL
90	NULL
bp	NULL
Pst	NULL
1	NULL
restriction	NULL
fragments	NULL
of	NULL
HK101/3	NULL
were	NULL
isolated	NULL
from	NULL
low	NULL
melting	NULL
agarose	NULL
,	NULL
end-labelled	NULL
and	NULL
used	NULL
for	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
assay	NULL
The	NULL
in	NULL
vitro	NULL
transcription	NULL
assay	NULL
with	NULL
the	NULL
use	NULL
of	NULL
whole	NULL
cell	NULL
HeLa	NULL
extracts	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
Manley	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

The	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
50	NULL
ul	NULL
volumes	NULL
,	NULL
containing	NULL
30	NULL
ul	NULL
of	NULL
HeLa	NULL
whole	NULL
cell	NULL
extract	NULL
,	NULL
5	NULL
ul	NULL
of	NULL
nucleoside	NULL
triphosphates	NULL
containing	NULL
5	NULL
mm	NULL
ATP	NULL
,	NULL
CTP	NULL
,	NULL
UTP	NULL
,	NULL
1	NULL
mm	NULL
GTP	NULL
with	NULL
10	NULL
uCi	NULL
of	NULL
[	NULL
a-	NULL
(	NULL
*P	NULL
)	NULL
GTP	NULL
]	NULL
(	NULL
New	NULL
Research	NULL
Products	NULL
)	NULL
,	NULL
and	NULL
0-2-0-5	NULL
ug	NULL
of	NULL
template	NULL
DNA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
or	NULL
control	NULL
buffer	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
2	NULL
ul	NULL
per	NULL
reaction	NULL
were	NULL
preincubated	NULL
with	NULL
the	NULL
DNA	NULL
template	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
before	NULL
initiation	NULL
of	NULL
transcription	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
measured	NULL
in	NULL
cell	NULL
equivalents	NULL
and	NULL
the	NULL
products	NULL
of	NULL
transcription	NULL
were	NULL
electrophoresed	NULL
in	NULL
14	NULL
%	NULL
agarose	NULL
gels	NULL
after	NULL
denaturation	NULL
with	NULL
glyoxol	NULL
.	NULL

DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
The	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
methodology	NULL
described	NULL
by	NULL
Landolfi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
(	NULL
1986	NULL
)	NULL
.	NULL

The	NULL
``	NULL
P-labelled	NULL
fragments	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
control	NULL
buffer	NULL
or	NULL
nuclear	NULL
extracts	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
ug	NULL
of	NULL
sheared	NULL
salmon	NULL
sperm	NULL
DNA	NULL
(	NULL
Pharmacia	NULL
)	NULL
and	NULL
in	NULL
some	NULL
experiments	NULL
with	NULL
1-8	NULL
ng	NULL
of	NULL
unlabelled	NULL
fragments	NULL
of	NULL
HK101/3	NULL
;	NULL
1-4	NULL
ng	NULL
of	NULL
P-labelied	NULL
fragments	NULL
and	NULL
4x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
.	NULL

The	NULL
binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
ul	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
electrophoresed	NULL
in	NULL
1-4	NULL
%	NULL
agarose	NULL
gels	NULL
containing	NULL
0-2	NULL
m	NULL
Tris	NULL
(	NULL
pH	NULL
8-3	NULL
)	NULL
,	NULL
0-1	NULL
m	NULL
boric	NULL
acid	NULL
and	NULL
0-2	NULL
mm	NULL
EDTA	NULL
.	NULL

These	NULL
were	NULL
run	NULL
for	NULL
3-4	NULL
hr	NULL
at	NULL
10V	NULL
/cm	NULL
.	NULL

All	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
autoradiographed	NULL
.	NULL

RESULTS	NULL
Enhancement	NULL
of	NULL
in	NULL
vitro	NULL
transcription	NULL
of	NULL
different	NULL
fragments	NULL
of	NULL
human	NULL
V	NULL
,	NULL
gene	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
human	NULL
lymphoid	NULL
neoplasms	NULL
We	NULL
have	NULL
used	NULL
fragments	NULL
of	NULL
variable	NULL
region	NULL
of	NULL
human	NULL
unrearranged	NULL
V	NULL
,	NULL
gene	NULL
(	NULL
clones	NULL
HK101/3	NULL
and	NULL
HK101/80	NULL
)	NULL
for	NULL
the	NULL
in	NULL
vitro	NULL
run-off	NULL
transcription	NULL
assay	NULL
.	NULL

The	NULL
HK	NULL
101/3	NULL
clone	NULL
represents	NULL
a	NULL
4-9	NULL
kb	NULL
fragment	NULL
containing	NULL
2-9	NULL
kb	NULL
of	NULL
the	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
and	NULL
1:5	NULL
kb	NULL
of	NULL
3	NULL
'	NULL
flanking	NULL
region	NULL
(	NULL
Bentley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

This	NULL
gene	NULL
is	NULL
subcloned	NULL
in	NULL
the	NULL
HindIII	NULL
,	NULL
EcoR1	NULL
site	NULL
of	NULL
pBR-322	NULL
and	NULL
a	NULL
restriction	NULL
map	NULL
of	NULL
this	NULL
clone	NULL
is	NULL
presented	NULL
in	NULL
the	NULL
top	NULL
of	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

In	NULL
the	NULL
run-off	NULL
transcription	NULL
assay	NULL
,	NULL
when	NULL
HK	NULL
101/3	NULL
is	NULL
linearized	NULL
with	NULL
HindIII	NULL
alone	NULL
it	NULL
gives	NULL
rise	NULL
to	NULL
2	NULL
kb	NULL
transcript	NULL
.	NULL

The	NULL
transcript	NULL
starts	NULL
at	NULL
the	NULL
cap	NULL
site	NULL
and	NULL
ends	NULL
at	NULL
the	NULL
HindIII	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
same	NULL
length	NULL
of	NULL
transcript	NULL
is	NULL
obtained	NULL
when	NULL
the	NULL
HK101/3	NULL
is	NULL
digested	NULL
with	NULL
both	NULL
BamHI	NULL
and	NULL
HindIII	NULL
,	NULL
since	NULL
the	NULL
5	NULL
flanking	NULL
region	NULL
sequences	NULL
from	NULL
BamHI	NULL
site	NULL
to	NULL
cap	NULL
site	NULL
are	NULL
not	NULL
transcribed	NULL
in	NULL
our	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
and	NULL
c	NULL
)	NULL
(	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
HK101/80	NULL
represents	NULL
a	NULL
subclone	NULL
of	NULL
HK101/3	NULL
.	NULL

It	NULL
is	NULL
a	NULL
558	NULL
bp	NULL
,	NULL
Pst	NULL
1	NULL
fragment	NULL
,	NULL
which	NULL
contains	NULL
130	NULL
bp	NULL
of	NULL
5	NULL
flanking	NULL
region	NULL
and	NULL
428	NULL
bp	NULL
of	NULL
the	NULL
V	NULL
,	NULL
coding	NULL
region	NULL
.	NULL

It	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
440	NULL
bp	NULL
transcript	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
,	NULL
b	NULL
and	NULL
c	NULL
)	NULL
,	NULL
(	NULL
Bentley	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

The	NULL
pBR-322	NULL
and	NULL
pTZ-19R	NULL
vector	NULL
sequences	NULL
were	NULL
not	NULL
separated	NULL
from	NULL
the	NULL
template	NULL
sequences	NULL
and	NULL
were	NULL
present	NULL
in	NULL
transcription	NULL
reactions	NULL
.	NULL

As	NULL
described	NULL
previously	NULL
,	NULL
transcription	NULL
of	NULL
the	NULL
HK101/3	NULL
clone	NULL
was	NULL
enhanced	NULL
10-22-fold	NULL
when	NULL
this	NULL
template	NULL
was	NULL
preincubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
human	NULL
large	NULL
non-cleaved	NULL
330	NULL
A.	NULL
E.	NULL
Kossakowska	NULL
&	NULL
S.	NULL
J.	NULL
Urbanski	NULL
2000	NULL
bp	NULL
I	NULL
I	NULL
HindIII	NULL
I	NULL
--	NULL
H	NULL
A	NULL
}	NULL
PstI	NULL
PstI	NULL
PstI	NULL
/	NULL
\	NULL
/	NULL
\	NULL
/	NULL
\	NULL
/	NULL
V	NULL
,	NULL
A\	NULL
/	NULL
cap	NULL
\	NULL
PstI	NULL
Z	NULL
\	NULL
Pst	NULL
I	NULL
440	NULL
bp	NULL
'octamer	NULL
'	NULL
vkcop	NULL
BamHI	NULL
EcoRI	NULL
HK	NULL
10	NULL
1/3	NULL
Pst	NULL
I	NULL
HK	NULL
10	NULL
1/80	NULL
(	NULL
a	NULL
)	NULL
(	NULL
i	NULL
)	NULL
_	NULL
(	NULL
ii	NULL
)	NULL
_	NULL
(	NULL
iii	NULL
)	NULL
(	NULL
b	NULL
)	NULL
(	NULL
i	NULL
)	NULL
(	NULL
ii	NULL
)	NULL
_	NULL
(	NULL
iii	NULL
)	NULL
(	NULL
c	NULL
)	NULL
(	NULL
i	NULL
)	NULL
_	NULL
(	NULL
ii	NULL
)	NULL
(	NULL
iii	NULL
)	NULL
-	NULL
HK	NULL
10	NULL
1/3	NULL
-2000	NULL
bp	NULL
,	NULL
-HK	NULL
10	NULL
1/8	NULL
-	NULL
440	NULL
bp	NULL
Figure	NULL
1	NULL
.	NULL

Schematic	NULL
restriction	NULL
map	NULL
of	NULL
HK	NULL
101/3	NULL
and	NULL
HK	NULL
101/80	NULL
clones	NULL
and	NULL
effects	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
human	NULL
lymphoid	NULL
neoplasms	NULL
on	NULL
their	NULL
in	NULL
vitro	NULL
transcription	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Lanes	NULL
(	NULL
i	NULL
)	NULL
-	NULL
(	NULL
iii	NULL
)	NULL
represent	NULL
reactions	NULL
in	NULL
which	NULL
0-2	NULL
ug	NULL
of	NULL
HK	NULL
101/80	NULL
digested	NULL
with	NULL
Pst	NULL
1	NULL
was	NULL
present	NULL
.	NULL

In	NULL
lane	NULL
(	NULL
i	NULL
)	NULL
the	NULL
template	NULL
was	NULL
preincubated	NULL
with	NULL
control	NULL
buffer	NULL
,	NULL
in	NULL
lane	NULL
(	NULL
ii	NULL
)	NULL
with	NULL
4x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
4	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
in	NULL
lane	NULL
(	NULL
iii	NULL
)	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
large	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
OCI1-LY	NULL
1	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Lanes	NULL
(	NULL
i	NULL
)	NULL
-	NULL
(	NULL
iii	NULL
)	NULL
represent	NULL
reactions	NULL
in	NULL
which	NULL
a	NULL
mixture	NULL
of	NULL
HK	NULL
101/80	NULL
digested	NULL
with	NULL
Pst	NULL
1	NULL
and	NULL
HK101/3	NULL
digested	NULL
with	NULL
both	NULL
HindIII	NULL
,	NULL
BamH1	NULL
(	NULL
total	NULL
DNA	NULL
concentration	NULL
was	NULL
0-5	NULL
ug/reaction	NULL
and	NULL
ratio	NULL
of	NULL
HK	NULL
101/80	NULL
to	NULL
HK101/3	NULL
was	NULL
2	NULL
:	NULL
3	NULL
)	NULL
was	NULL
present	NULL
.	NULL

Vector	NULL
DNA	NULL
sequences	NULL
(	NULL
pBR-322	NULL
and	NULL
pTZ-19R	NULL
)	NULL
were	NULL
not	NULL
removed	NULL
from	NULL
the	NULL
reactions	NULL
.	NULL

In	NULL
lane	NULL
(	NULL
i	NULL
)	NULL
the	NULL
templates	NULL
were	NULL
preincubated	NULL
with	NULL
control	NULL
buffer	NULL
,	NULL
in	NULL
lane	NULL
(	NULL
ii	NULL
)	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extract	NULL
form	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
2	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
in	NULL
lane	NULL
(	NULL
iii	NULL
)	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
large	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
OCI1-LY1	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

HK101/3	NULL
digested	NULL
with	NULL
HindIII	NULL
,	NULL
BamHI	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
2000	NULL
bp	NULL
transcript	NULL
and	NULL
HK	NULL
101/80	NULL
digested	NULL
with	NULL
Pstl	NULL
to	NULL
a	NULL
440	NULL
bp	NULL
transcript	NULL
.	NULL

Densitometrically	NULL
measured	NULL
ratio	NULL
of	NULL
HK	NULL
101/80	NULL
:	NULL
HK	NULL
101/3	NULL
transcripts	NULL
is	NULL
40-0	NULL
in	NULL
lane	NULL
(	NULL
i	NULL
)	NULL
,	NULL
4-1	NULL
in	NULL
lane	NULL
(	NULL
ii	NULL
)	NULL
and	NULL
4-0	NULL
in	NULL
lane	NULL
(	NULL
iii	NULL
)	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Lane	NULL
(	NULL
i	NULL
)	NULL
-	NULL
(	NULL
iii	NULL
)	NULL
represent	NULL
reactions	NULL
in	NULL
which	NULL
0-2	NULL
ug	NULL
of	NULL
HK	NULL
101/80	NULL
digested	NULL
with	NULL
Pst	NULL
1	NULL
was	NULL
preincubated	NULL
with	NULL
control	NULL
buffer	NULL
in	NULL
lane	NULL
(	NULL
i	NULL
)	NULL
and	NULL
in	NULL
lanes	NULL
(	NULL
ii	NULL
)	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
with	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
1	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

The	NULL
concentrations	NULL
of	NULL
extract	NULL
were	NULL
1	NULL
x	NULL
10°	NULL
and	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
,	NULL
respectively	NULL
;	NULL
0-3	NULL
ug	NULL
of	NULL
HK101/3	NULL
digested	NULL
with	NULL
HindIII	NULL
was	NULL
added	NULL
10	NULL
min	NULL
later	NULL
and	NULL
10	NULL
min	NULL
before	NULL
initiation	NULL
of	NULL
transcription	NULL
.	NULL

cell	NULL
,	NULL
small	NULL
non-cleaved	NULL
cell	NULL
(	NULL
Burkitt	NULL
's	NULL
)	NULL
lymphomas	NULL
and	NULL
plasmacytomas	NULL
(	NULL
Kossakowska	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

These	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
template	NULL
was	NULL
linearized	NULL
with	NULL
HindIII	NULL
.	NULL

Digestion	NULL
of	NULL
the	NULL
template	NULL
with	NULL
BamH1	NULL
in	NULL
addition	NULL
to	NULL
HindIII	NULL
did	NULL
not	NULL
diminish	NULL
the	NULL
enhancing	NULL
effects	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
tested	NULL
.	NULL

These	NULL
data	NULL
indicated	NULL
that	NULL
the	NULL
DNA	NULL
region	NULL
responsible	NULL
for	NULL
the	NULL
action	NULL
of	NULL
the	NULL
enhancing	NULL
transacting	NULL
factors	NULL
is	NULL
located	NULL
within	NULL
1150	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
cap	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

To	NULL
further	NULL
localize	NULL
the	NULL
regulatory	NULL
sequences	NULL
responsible	NULL
for	NULL
the	NULL
in	NULL
vitro	NULL
transcription	NULL
enhancement	NULL
of	NULL
HK101/3	NULL
,	NULL
we	NULL
have	NULL
used	NULL
the	NULL
HKIO1/80	NULL
subclone	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
V	NULL
,	NULL
coding	NULL
region	NULL
,	NULL
and	NULL
130	NULL
bp	NULL
of	NULL
the	NULL
upstream	NULL
5	NULL
'	NULL
flanking	NULL
sequences	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
that	NULL
this	NULL
region	NULL
is	NULL
sufficient	NULL
for	NULL
accurate	NULL
initiation	NULL
of	NULL
transcription	NULL
and	NULL
contains	NULL
the	NULL
'octamer	NULL
'	NULL
sequence	NULL
that	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
tissue-specific	NULL
expression	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
(	NULL
Bentley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
;	NULL
Falkner	NULL
&	NULL
Zachau	NULL
,	NULL
1984	NULL
;	NULL
Staudt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
transcription	NULL
of	NULL
this	NULL
subclone	NULL
was	NULL
not	NULL
enhanced	NULL
by	NULL
any	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
used	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lane	NULL
(	NULL
i	NULL
)	NULL
represents	NULL
a	NULL
control	NULL
reaction	NULL
in	NULL
which	NULL
the	NULL
HK101/80	NULL
clone	NULL
was	NULL
preincubated	NULL
with	NULL
control	NULL
buffer	NULL
.	NULL

In	NULL
lane	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
template	NULL
was	NULL
preincubated	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
human	NULL
plasmacytoma	NULL
and	NULL
in	NULL
lane	NULL
(	NULL
iii	NULL
)	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
large	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
.	NULL

No	NULL
differences	NULL
in	NULL
levels	NULL
of	NULL
transcription	NULL
were	NULL
seen	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
used	NULL
was	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
and	NULL
the	NULL
DNA	NULL
concentration	NULL
was	NULL
0-2	NULL
ug	NULL
per	NULL
reaction	NULL
(	NULL
the	NULL
optimum	NULL
established	NULL
previously	NULL
;	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

When	NULL
the	NULL
HK	NULL
101/80	NULL
was	NULL
premixed	NULL
with	NULL
HK101/3	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
and	NULL
c	NULL
)	NULL
and	NULL
preincubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
human	NULL
plasmacytoma	NULL
(	NULL
lane	NULL
ii	NULL
)	NULL
or	NULL
large	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
lane	NULL
iii	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
)	NULL
,	NULL
the	NULL
enhancement	NULL
of	NULL
HK	NULL
101/3	NULL
was	NULL
10-fold	NULL
when	NULL
measured	NULL
by	NULL
comparing	NULL
the	NULL
ratio	NULL
between	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
two	NULL
bands	NULL
.	NULL

Measured	NULL
separately	NULL
the	NULL
HK101/3	NULL
enhancement	NULL
was	NULL
10-fold	NULL
in	NULL
both	NULL
lanes	NULL
,	NULL
and	NULL
that	NULL
of	NULL
HK101/80	NULL
1-15-	NULL
in	NULL
lane	NULL
(	NULL
ii	NULL
)	NULL
and	NULL
1:02-fold	NULL
in	NULL
lane	NULL
(	NULL
iii	NULL
)	NULL
.	NULL

The	NULL
slight	NULL
increase	NULL
of	NULL
the	NULL
HK	NULL
101/80	NULL
transcription	NULL
does	NULL
not	NULL
appear	NULL
significant	NULL
and	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
pipetting	NULL
error	NULL
.	NULL

Preincubation	NULL
of	NULL
HK101/80	NULL
with	NULL
different	NULL
amounts	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
human	NULL
plasmacytoma	NULL
did	NULL
not	NULL
remove	NULL
the	NULL
enhancing	NULL
activity	NULL
for	NULL
HK101/3	NULL
(	NULL
Fig	NULL
.	NULL

1c	NULL
)	NULL
.	NULL

The	NULL
enhancement	NULL
of	NULL
HK101/3	NULL
was	NULL
10-fold	NULL
over	NULL
the	NULL
control	NULL
,	NULL
while	NULL
the	NULL
transcription	NULL
of	NULL
HK101/80	NULL
showed	NULL
Novel	NULL
!	NULL

gene	NULL
promoter	NULL
region	NULL
only	NULL
a	NULL
slight	NULL
increase	NULL
which	NULL
is	NULL
probably	NULL
related	NULL
to	NULL
the	NULL
increased	NULL
background	NULL
radioactivity	NULL
.	NULL

In	NULL
previously	NULL
published	NULL
data	NULL
(	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
the	NULL
levels	NULL
of	NULL
transcription	NULL
from	NULL
HK101/3	NULL
were	NULL
compared	NULL
with	NULL
the	NULL
levels	NULL
of	NULL
transcription	NULL
from	NULL
the	NULL
Adenovirus	NULL
II	NULL
major	NULL
late	NULL
promoter	NULL
(	NULL
AdII	NULL
)	NULL
.	NULL

The	NULL
Ad	NULL
II	NULL
transcript	NULL
has	NULL
a	NULL
similar	NULL
length	NULL
(	NULL
442	NULL
bp	NULL
)	NULL
to	NULL
that	NULL
of	NULL
HK	NULL
101/80	NULL
(	NULL
440	NULL
bp	NULL
)	NULL
and	NULL
similar	NULL
enhancement	NULL
of	NULL
HK101/3	NULL
(	NULL
10-12-fold	NULL
)	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
mixtures	NULL
of	NULL
both	NULL
templates	NULL
.	NULL

HK101/3	NULL
gene	NULL
,	NULL
0-2	NULL
ug	NULL
,	NULL
transcribed	NULL
without	NULL
nuclear	NULL
extracts	NULL
gave	NULL
rise	NULL
to	NULL
approximately	NULL
0-002	NULL
transcripts/gene/hr	NULL
(	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
of	NULL
HK	NULL
101/80	NULL
was	NULL
40	NULL
times	NULL
more	NULL
efficient	NULL
and	NULL
when	NULL
0-2	NULL
ug	NULL
of	NULL
this	NULL
template	NULL
was	NULL
transcribed	NULL
without	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
,	NULL
b	NULL
and	NULL
c	NULL
)	NULL
approximately	NULL
0-08	NULL
transcripts/gene/hr	NULL
were	NULL
obtained	NULL
.	NULL

These	NULL
differences	NULL
are	NULL
not	NULL
well	NULL
understood	NULL
at	NULL
the	NULL
present	NULL
time	NULL
.	NULL

It	NULL
has	NULL
,	NULL
however	NULL
,	NULL
been	NULL
described	NULL
previously	NULL
that	NULL
the	NULL
larger	NULL
size	NULL
fragments	NULL
of	NULL
the	NULL
V	NULL
;	NULL
,	NULL
promoter	NULL
are	NULL
less	NULL
efficient	NULL
than	NULL
the	NULL
shorter	NULL
ones	NULL
in	NULL
the	NULL
in	NULL
vivo	NULL
transcription	NULL
assays	NULL
(	NULL
Doyen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

From	NULL
the	NULL
present	NULL
data	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
the	NULL
sequences	NULL
responsible	NULL
for	NULL
the	NULL
in	NULL
vitro	NULL
enhancing	NULL
effects	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
human	NULL
B-cell	NULL
neoplasms	NULL
are	NULL
not	NULL
located	NULL
within	NULL
the	NULL
130	NULL
bp	NULL
of	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
of	NULL
the	NULL
HK	NULL
101/80	NULL
clone	NULL
.	NULL

Instead	NULL
they	NULL
appear	NULL
to	NULL
be	NULL
localized	NULL
upstream	NULL
of	NULL
the	NULL
HK	NULL
101/80	NULL
.	NULL

Binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
human	NULL
lymphoid	NULL
neoplasms	NULL
to	NULL
specific	NULL
upstream	NULL
sequences	NULL
of	NULL
human	NULL
V	NULL
,	NULL
gene	NULL
We	NULL
have	NULL
analysed	NULL
three	NULL
fragments	NULL
of	NULL
the	NULL
HK	NULL
101/3	NULL
gene	NULL
with	NULL
the	NULL
use	NULL
of	NULL
a	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
utilizing	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
human	NULL
lymphoid	NULL
and	NULL
non-lymphoid	NULL
neoplasms	NULL
.	NULL

These	NULL
fragments	NULL
are	NULL
schematically	NULL
presented	NULL
in	NULL
the	NULL
top	NULL
of	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

The	NULL
558	NULL
bp	NULL
fragment	NULL
corresponding	NULL
to	NULL
HK	NULL
101/80	NULL
clone	NULL
gave	NULL
rise	NULL
to	NULL
three	NULL
distinct	NULL
shift	NULL
bands	NULL
when	NULL
preincubated	NULL
with	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
4	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
large	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
OCI1-LY1	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
small	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
Raji	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
HeLa	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
lanes	NULL
ii-v	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
giving	NULL
rise	NULL
to	NULL
an	NULL
identical	NULL
shift	NULL
pattern	NULL
with	NULL
all	NULL
the	NULL
extracts	NULL
used	NULL
.	NULL

Other	NULL
nuclear	NULL
extracts	NULL
tested	NULL
included	NULL
:	NULL
two	NULL
plasmacytomas	NULL
(	NULL
fresh	NULL
specimen	NULL
and	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
two	NULL
fresh	NULL
specimens	NULL
of	NULL
small	NULL
cleaved	NULL
cell	NULL
lymphomas	NULL
,	NULL
pre	NULL
B-cell	NULL
leukaemia	NULL
,	NULL
three	NULL
cell	NULL
lines	NULL
of	NULL
T-cell	NULL
acute	NULL
lymphoblastic	NULL
leukae-mias	NULL
,	NULL
K562	NULL
cell	NULL
line	NULL
of	NULL
chronic	NULL
myelogenous	NULL
leukaemia	NULL
and	NULL
fresh	NULL
specimen	NULL
of	NULL
human	NULL
breast	NULL
carcinoma	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
nuclear	NULL
extracts	NULL
used	NULL
was	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
,	NULL
as	NULL
it	NULL
was	NULL
found	NULL
to	NULL
be	NULL
an	NULL
optimum	NULL
for	NULL
all	NULL
the	NULL
extracts	NULL
used	NULL
in	NULL
this	NULL
assay	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Different	NULL
amounts	NULL
of	NULL
DNA	NULL
used	NULL
in	NULL
the	NULL
shift	NULL
assay	NULL
gave	NULL
rise	NULL
to	NULL
the	NULL
same	NULL
shift	NULL
band	NULL
pattern	NULL
with	NULL
the	NULL
use	NULL
of	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
human	NULL
plasmacytoma	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
)	NULL
.	NULL

The	NULL
90	NULL
bp	NULL
fragment	NULL
located	NULL
directly	NULL
upstream	NULL
of	NULL
HK	NULL
101/80	NULL
clone	NULL
was	NULL
not	NULL
shifted	NULL
with	NULL
any	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

2c	NULL
)	NULL
.	NULL

The	NULL
only	NULL
fragment	NULL
which	NULL
gave	NULL
rise	NULL
to	NULL
specific	NULL
band	NULL
shift	NULL
was	NULL
the	NULL
920	NULL
bp	NULL
,	NULL
Pst	NULL
1	NULL
fragment	NULL
corresponding	NULL
to	NULL
HK101/2	NULL
clone	NULL
described	NULL
by	NULL
Bentley	NULL
&	NULL
Rabbits	NULL
(	NULL
1981	NULL
)	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
.	NULL

This	NULL
fragment	NULL
is	NULL
located	NULL
210	NULL
bp	NULL
from	NULL
the	NULL
cap	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

When	NULL
preincubated	NULL
with	NULL
nuclear	NULL
extract	NULL
(	NULL
4x	NULL
10°	NULL
cell	NULL
equivalents	NULL
)	NULL
derived	NULL
from	NULL
human	NULL
plasmacytoma	NULL
it	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
distinct	NULL
band	NULL
shift	NULL
(	NULL
Fig	NULL
.	NULL

2d	NULL
,	NULL
lane	NULL
ii	NULL
)	NULL
.	NULL

When	NULL
this	NULL
fragment	NULL
was	NULL
preincubated	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
HeLa	NULL
cells	NULL
(	NULL
lane	NULL
iii	NULL
)	NULL
,	NULL
large	NULL
non-cleaved	NULL
cell	NULL
(	NULL
lane	NULL
iv	NULL
)	NULL
and	NULL
small	NULL
non-cleaved	NULL
cell	NULL
lymphomas	NULL
(	NULL
Burkitt	NULL
's	NULL
,	NULL
lane	NULL
v	NULL
)	NULL
,	NULL
no	NULL
detectable	NULL
shift	NULL
was	NULL
noted	NULL
331	NULL
HK	NULL
10	NULL
1/80	NULL
HK	NULL
10	NULL
1/2	NULL
A	NULL
A	NULL
EcoRI	NULL
gone	NULL
...	NULL
d	NULL
|	NULL
I	NULL
HindIHI	NULL
PstI	NULL
Pst	NULL
I1	NULL
Pst	NULL
I	NULL
l	NULL
Pst	NULL
L	NULL
BomHL	NULL
P	NULL
;	NULL
I	NULL
4	NULL
1	NULL
}	NULL
i	NULL
``	NULL
VFW	NULL
]	NULL
558	NULL
bp	NULL
|	NULL
920	NULL
bp	NULL
LJ	NULL
90	NULL
bp	NULL
(	NULL
a	NULL
)	NULL
(	NULL
i	NULL
)	NULL
(	NULL
ii	NULL
)	NULL
(	NULL
iii	NULL
)	NULL
(	NULL
iv	NULL
)	NULL
(	NULL
v	NULL
)	NULL
(	NULL
b	NULL
)	NULL
(	NULL
i	NULL
)	NULL
(	NULL
ii	NULL
)	NULL
(	NULL
iii	NULL
)	NULL
(	NULL
iv	NULL
)	NULL
#	NULL
k—ssebp—	NULL
ﬁnd-	NULL
“	NULL
w	NULL
(	NULL
e	NULL
)	NULL
(	NULL
i	NULL
)	NULL
(	NULL
ii	NULL
)	NULL
(	NULL
iii	NULL
)	NULL
(	NULL
iv	NULL
)	NULL
(	NULL
a	NULL
)	NULL
(	NULL
i	NULL
)	NULL
_	NULL
(	NULL
ii	NULL
)	NULL
(	NULL
ii	NULL
)	NULL
(	NULL
iv	NULL
)	NULL
(	NULL
v	NULL
)	NULL
«	NULL
me	NULL
«	NULL
ane	NULL
«	NULL
anh	NULL
eB	NULL
-90	NULL
1	NULL
;	NULL
Figure	NULL
2	NULL
.	NULL

Binding	NULL
of	NULL
nuclear	NULL
factors	NULL
derived	NULL
from	NULL
human	NULL
neoplasms	NULL
to	NULL
different	NULL
restriction	NULL
fragments	NULL
of	NULL
HKIO1/3	NULL
clone	NULL
.	NULL

(	NULL
a	NULL
)	NULL
All	NULL
reactions	NULL
contained	NULL
4	NULL
ng	NULL
of	NULL
*P	NULL
end-labelled	NULL
558	NULL
bp	NULL
Pst	NULL
1	NULL
restriction	NULL
fragment	NULL
corresponding	NULL
to	NULL
HK101/80	NULL
subclone	NULL
.	NULL

In	NULL
lane	NULL
(	NULL
i	NULL
)	NULL
this	NULL
fragment	NULL
was	NULL
preincubated	NULL
with	NULL
control	NULL
buffer	NULL
and	NULL
in	NULL
lanes	NULL
(	NULL
ii	NULL
)	NULL
-	NULL
(	NULL
v	NULL
)	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
:	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
2	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
large	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
OCI1-LY1	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
small	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
Raji	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
from	NULL
human	NULL
cervical	NULL
adenocarcinoma	NULL
(	NULL
HeLa	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
All	NULL
reactions	NULL
contained	NULL
P	NULL
end-labelied	NULL
558	NULL
bp	NULL
Pst	NULL
1	NULL
,	NULL
restriction	NULL
fragment	NULL
corresponding	NULL
to	NULL
HK101/80	NULL
subclone	NULL
.	NULL

In	NULL
lane	NULL
(	NULL
i	NULL
)	NULL
this	NULL
fragment	NULL
was	NULL
preincubated	NULL
with	NULL
control	NULL
buffer	NULL
.	NULL

In	NULL
lanes	NULL
(	NULL
ii	NULL
)	NULL
-	NULL
(	NULL
iv	NULL
)	NULL
,	NULL
4	NULL
,	NULL
2	NULL
and	NULL
1	NULL
ng	NULL
of	NULL
this	NULL
fragment	NULL
were	NULL
preincubated	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
24	NULL
cell	NULL
line	NULL
)	NULL
.	NULL

(	NULL
c	NULL
)	NULL
All	NULL
reactions	NULL
contained	NULL
2	NULL
ng	NULL
of	NULL
P	NULL
end-labelled	NULL
90	NULL
bp	NULL
Pst	NULL
1	NULL
restriction	NULL
fragment	NULL
located	NULL
directly	NULL
upstream	NULL
from	NULL
the	NULL
fragment	NULL
present	NULL
in	NULL
(	NULL
a	NULL
)	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
preincubated	NULL
with	NULL
control	NULL
buffer	NULL
(	NULL
lane	NULL
i	NULL
)	NULL
and	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
:	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
4	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
large	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
OC1-LY1	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
cervical	NULL
adenocarcinoma	NULL
(	NULL
HeLa	NULL
cell	NULL
line	NULL
)	NULL
(	NULL
lanes	NULL
ii-iv	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

(	NULL
d	NULL
)	NULL
All	NULL
reactions	NULL
contained	NULL
4	NULL
ng	NULL
of	NULL
P	NULL
end-labelled	NULL
920	NULL
bp	NULL
Pst	NULL
1	NULL
restriction	NULL
fragment	NULL
corresponding	NULL
to	NULL
HK101/2	NULL
subclone	NULL
.	NULL

In	NULL
lane	NULL
(	NULL
i	NULL
)	NULL
this	NULL
fragment	NULL
was	NULL
preincubated	NULL
with	NULL
control	NULL
buffer	NULL
and	NULL
in	NULL
lanes	NULL
(	NULL
ii	NULL
)	NULL
-	NULL
(	NULL
v	NULL
)	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
:	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
2	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
cervical	NULL
adenocarcinoma	NULL
(	NULL
HeLa	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
large	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
OC1-LY1	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
small	NULL
non-cleaved	NULL
cell	NULL
lymphoma	NULL
(	NULL
Raji	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Products	NULL
of	NULL
all	NULL
reactions	NULL
were	NULL
electrophoresed	NULL
in	NULL
14	NULL
%	NULL
agarose	NULL
gels	NULL
containing	NULL
0-1	NULL
M	NULL
Tris	NULL
(	NULL
pH	NULL
8-3	NULL
)	NULL
,	NULL
0-1	NULL
M	NULL
boric	NULL
acid	NULL
and	NULL
2	NULL
mM	NULL
EDTA	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
.	NULL

None	NULL
of	NULL
the	NULL
other	NULL
extracts	NULL
used	NULL
had	NULL
any	NULL
effects	NULL
on	NULL
the	NULL
mobility	NULL
of	NULL
HK101/2	NULL
.	NULL

These	NULL
included	NULL
:	NULL
non-B	NULL
human	NULL
lymphoid	NULL
neoplasms	NULL
,	NULL
carcinomas	NULL
,	NULL
as	NULL
well	NULL
as	NULL
small	NULL
cleaved	NULL
B-cell	NULL
lymphomas	NULL
.	NULL

le	NULL
-	NULL
920	NULL
bp	NULL
332	NULL
A.	NULL
E.	NULL
Kossakowska	NULL
&	NULL
S.	NULL
J.	NULL
Urbanski	NULL
(	NULL
a	NULL
)	NULL
(	NULL
i	NULL
)	NULL
(	NULL
ii	NULL
)	NULL
(	NULL
iil	NULL
)	NULL
(	NULL
iv	NULL
)	NULL
(	NULL
v	NULL
)	NULL
unica	NULL
:	NULL
Figure	NULL
3	NULL
.	NULL

Competition	NULL
between	NULL
*P-labelled	NULL
HK101/2	NULL
and	NULL
non-labelled	NULL
HK101/3	NULL
and	NULL
HK101/80	NULL
clones	NULL
for	NULL
binding	NULL
of	NULL
nuclear	NULL
protein	NULL
factors	NULL
derived	NULL
from	NULL
human	NULL
plasmacytoma	NULL
.	NULL

(	NULL
a	NULL
)	NULL
All	NULL
reactions	NULL
conatined	NULL
4	NULL
ng	NULL
of	NULL
P	NULL
end-labelled	NULL
920	NULL
bp	NULL
fragment	NULL
corresponding	NULL
to	NULL
HK101/2	NULL
clone	NULL
.	NULL

4x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
the	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
human	NULL
plamacytoma	NULL
(	NULL
IgA	NULL
4	NULL
cell	NULL
line	NULL
)	NULL
was	NULL
preincubated	NULL
with	NULL
8	NULL
,	NULL
4	NULL
,	NULL
2	NULL
and	NULL
1	NULL
ng	NULL
of	NULL
non-labelled	NULL
HK101/3	NULL
clone	NULL
(	NULL
lanes	NULL
i-iv	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

In	NULL
lane	NULL
(	NULL
v	NULL
)	NULL
only	NULL
the	NULL
labelled	NULL
fragment	NULL
was	NULL
preincubated	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
the	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
IgA	NULL
4	NULL
cell	NULL
line	NULL
.	NULL

(	NULL
b	NULL
)	NULL
All	NULL
reactions	NULL
contained	NULL
4	NULL
ng	NULL
of	NULL
*	NULL
P	NULL
end-labelled	NULL
920	NULL
bp	NULL
fragment	NULL
corresponding	NULL
to	NULL
HK101/2	NULL
clone	NULL
.	NULL

4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
the	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
human	NULL
plasmacytoma	NULL
(	NULL
IgA	NULL
4	NULL
cell	NULL
line	NULL
)	NULL
was	NULL
preincubated	NULL
with	NULL
8	NULL
,	NULL
4	NULL
and	NULL
2	NULL
ng	NULL
of	NULL
non-labelled	NULL
HK101/80	NULL
clone	NULL
(	NULL
lanes	NULL
i-iii	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

In	NULL
lane	NULL
(	NULL
iv	NULL
)	NULL
only	NULL
the	NULL
labelled	NULL
fragment	NULL
was	NULL
preincubated	NULL
with	NULL
4	NULL
x	NULL
10°	NULL
cell	NULL
equivalents	NULL
of	NULL
the	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
IgA	NULL
2	NULL
cell	NULL
line	NULL
.	NULL

Preincubation	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
non-labelled	NULL
HK101/3	NULL
DNA	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
human	NULL
plasmacytomas	NULL
to	NULL
shift	NULL
the	NULL
fragment	NULL
corresponding	NULL
to	NULL
HK	NULL
101/2	NULL
clone	NULL
(	NULL
Fig	NULL
3a	NULL
)	NULL
,	NULL
but	NULL
preincubation	NULL
with	NULL
HK	NULL
101/80	NULL
did	NULL
not	NULL
show	NULL
such	NULL
a	NULL
specific	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3b	NULL
)	NULL
.	NULL

DISCUSSION	NULL
It	NULL
is	NULL
known	NULL
that	NULL
the	NULL
production	NULL
of	NULL
immunoglobulins	NULL
increases	NULL
during	NULL
B-cell	NULL
differentiation	NULL
(	NULL
Lamson	NULL
&	NULL
Koshland	NULL
,	NULL
1984	NULL
)	NULL
.	NULL

We	NULL
were	NULL
able	NULL
to	NULL
show	NULL
in	NULL
our	NULL
model	NULL
that	NULL
immunoglobulin	NULL
gene-specific	NULL
transcription	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
this	NULL
increase	NULL
of	NULL
the	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
by	NULL
human	NULL
lymphoid	NULL
neoplasms	NULL
(	NULL
Kossakowska	NULL
er	NULL
a/	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

With	NULL
the	NULL
use	NULL
of	NULL
similar	NULL
methods	NULL
it	NULL
had	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
hemin-induced	NULL
production	NULL
of	NULL
haemoglobin	NULL
in	NULL
K	NULL
562	NULL
cells	NULL
is	NULL
also	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
B-globin	NULL
family	NULL
gene-specific	NULL
transacting	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
(	NULL
Bazett-Jones	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

Similar	NULL
mechanisms	NULL
controlling	NULL
the	NULL
tissue	NULL
and	NULL
differentiation	NULL
stage-specific	NULL
expression	NULL
of	NULL
eukaryotic	NULL
genes	NULL
may	NULL
,	NULL
therefore	NULL
,	NULL
operate	NULL
for	NULL
different	NULL
classes	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
previously	NULL
published	NULL
data	NULL
suggesting	NULL
that	NULL
different	NULL
controlling	NULL
mechanisms	NULL
may	NULL
operate	NULL
at	NULL
different	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
(	NULL
Sen	NULL
&	NULL
Baltimore	NULL
,	NULL
1986a	NULL
;	NULL
Hromas	NULL
&	NULL
Van	NULL
Ness	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
previous	NULL
studies	NULL
concentrated	NULL
on	NULL
the	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF-xB	NULL
(	NULL
Sen	NULL
&	NULL
Baltimore	NULL
,	NULL
1986a	NULL
;	NULL
Atchinson	NULL
&	NULL
Perry	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

In	NULL
our	NULL
study	NULL
we	NULL
have	NULL
used	NULL
only	NULL
promoter	NULL
sequences	NULL
of	NULL
human	NULL
unrearranged	NULL
V	NULL
,	NULL
gene	NULL
,	NULL
which	NULL
is	NULL
transcriptionally	NULL
'silent	NULL
'	NULL
in	NULL
vivo	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
by	NULL
an	NULL
in	NULL
vitro	NULL
assay	NULL
that	NULL
this	NULL
gene	NULL
contains	NULL
a	NULL
functional	NULL
promoter	NULL
and	NULL
can	NULL
be	NULL
efficiently	NULL
transcribed	NULL
in	NULL
vitro	NULL
with	NULL
the	NULL
use	NULL
of	NULL
whole	NULL
cell	NULL
HeLa	NULL
extracts	NULL
(	NULL
Bentley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
;	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

Both	NULL
HK101/3	NULL
and	NULL
HK	NULL
101/80	NULL
clones	NULL
contain	NULL
functional	NULL
promoters	NULL
and	NULL
it	NULL
is	NULL
known	NULL
that	NULL
the	NULL
sequences	NULL
between	NULL
-90	NULL
and	NULL
-160	NULL
base	NULL
pairs	NULL
upstream	NULL
of	NULL
the	NULL
coding	NULL
region	NULL
are	NULL
essential	NULL
for	NULL
correct	NULL
transcriptional	NULL
initiation	NULL
(	NULL
Falkner	NULL
&	NULL
Zachau	NULL
,	NULL
1984	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
sequences	NULL
further	NULL
upstream	NULL
of	NULL
this	NULL
region	NULL
may	NULL
be	NULL
necessary	NULL
for	NULL
tissue-	NULL
and	NULL
stage-specific	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
(	NULL
Pospelov	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
.	NULL

The	NULL
HK101/3	NULL
gene	NULL
containing	NULL
29	NULL
kb	NULL
of	NULL
these	NULL
sequences	NULL
was	NULL
chosen	NULL
for	NULL
the	NULL
initial	NULL
experiments	NULL
(	NULL
Kossakowska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
transcription	NULL
of	NULL
the	NULL
HK101/80	NULL
clone	NULL
containing	NULL
only	NULL
130	NULL
bp	NULL
of	NULL
the	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
was	NULL
more	NULL
efficient	NULL
in	NULL
our	NULL
in	NULL
vitro	NULL
assay	NULL
but	NULL
its	NULL
transcription	NULL
was	NULL
not	NULL
enhanced	NULL
by	NULL
any	NULL
of	NULL
the	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
used	NULL
.	NULL

These	NULL
results	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
higher	NULL
base	NULL
line	NULL
transcription	NULL
levels	NULL
of	NULL
this	NULL
clone	NULL
,	NULL
but	NULL
it	NULL
is	NULL
also	NULL
likely	NULL
that	NULL
the	NULL
region	NULL
responsible	NULL
for	NULL
the	NULL
enhancement	NULL
of	NULL
in	NULL
vitro	NULL
transcription	NULL
of	NULL
the	NULL
V	NULL
,	NULL
gene	NULL
is	NULL
located	NULL
further	NULL
upstream	NULL
from	NULL
the	NULL
cap	NULL
site	NULL
.	NULL

This	NULL
hypothesis	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
the	NULL
results	NULL
of	NULL
the	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

The	NULL
558	NULL
bp	NULL
HK101/80	NULL
clone	NULL
,	NULL
which	NULL
contains	NULL
130	NULL
bp	NULL
of	NULL
sequences	NULL
within	NULL
the	NULL
5	NULL
flanking	NULL
promoter	NULL
region	NULL
and	NULL
was	NULL
not	NULL
enhanced	NULL
by	NULL
any	NULL
of	NULL
the	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
used	NULL
,	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
non-specific	NULL
mobility	NULL
shift	NULL
pattern	NULL
as	NULL
observed	NULL
with	NULL
the	NULL
DNA	NULL
binding	NULL
assay	NULL
.	NULL

With	NULL
the	NULL
use	NULL
of	NULL
this	NULL
assay	NULL
we	NULL
have	NULL
observed	NULL
three	NULL
distinct	NULL
shift	NULL
bands	NULL
similar	NULL
to	NULL
those	NULL
described	NULL
previously	NULL
(	NULL
Staudt	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

Recently	NULL
published	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
complexity	NULL
and	NULL
multiplicity	NULL
of	NULL
the	NULL
observed	NULL
shift	NULL
bands	NULL
may	NULL
be	NULL
related	NULL
to	NULL
limited	NULL
proteolytic	NULL
cleavage	NULL
of	NULL
the	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
during	NULL
nuclear	NULL
extract	NULL
preparation	NULL
(	NULL
Mather	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
stage-specific	NULL
differences	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
transacting	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
during	NULL
B-cell	NULL
differentiation	NULL
are	NULL
related	NULL
to	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
proteases	NULL
in	NULL
more	NULL
differentiated	NULL
B-cell	NULL
tumours	NULL
(	NULL
e.g	NULL
.	NULL

plasmacytomas	NULL
)	NULL
and	NULL
after	NULL
mitogen	NULL
stimulation	NULL
.	NULL

However	NULL
,	NULL
we	NULL
did	NULL
not	NULL
see	NULL
any	NULL
difference	NULL
in	NULL
the	NULL
patterns	NULL
of	NULL
DNA-protein	NULL
complex	NULL
mobility	NULL
with	NULL
the	NULL
use	NULL
of	NULL
lymphoid	NULL
and	NULL
non-lymphoid	NULL
nuclear	NULL
extracts	NULL
.	NULL

No	NULL
differences	NULL
were	NULL
observed	NULL
with	NULL
the	NULL
use	NULL
of	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
B-cell	NULL
neoplasms	NULL
corresponding	NULL
to	NULL
different	NULL
stages	NULL
of	NULL
B-cell	NULL
maturation	NULL
.	NULL

This	NULL
discrepancy	NULL
is	NULL
not	NULL
well	NULL
understood	NULL
but	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
differences	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
.	NULL

We	NULL
have	NULL
used	NULL
the	NULL
methodology	NULL
described	NULL
by	NULL
Bazett-Jones	NULL
et	NULL
al	NULL
(	NULL
1985	NULL
)	NULL
while	NULL
the	NULL
others	NULL
have	NULL
used	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
,	NULL
Lebovitz	NULL
&	NULL
Roeder	NULL
(	NULL
1983	NULL
)	NULL
or	NULL
methods	NULL
described	NULL
recently	NULL
by	NULL
Mather	NULL
(	NULL
1988	NULL
)	NULL
.	NULL

Different	NULL
protein	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
may	NULL
be	NULL
isolated	NULL
with	NULL
the	NULL
use	NULL
of	NULL
these	NULL
different	NULL
methods	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
extracts	NULL
(	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
at	NULL
the	NULL
same	NULL
time	NULL
were	NULL
used	NULL
in	NULL
both	NULL
Novel	NULL
gene	NULL
promoter	NULL
region	NULL
333	NULL
assays	NULL
)	NULL
had	NULL
not	NULL
only	NULL
shown	NULL
the	NULL
binding	NULL
affinity	NULL
for	NULL
specific	NULL
DNA	NULL
sequences	NULL
,	NULL
but	NULL
were	NULL
also	NULL
active	NULL
in	NULL
the	NULL
functional	NULL
in	NULL
vitro	NULL
transcription	NULL
assay	NULL
.	NULL

Therefore	NULL
,	NULL
even	NULL
if	NULL
they	NULL
were	NULL
partially	NULL
degraded	NULL
by	NULL
the	NULL
proteases	NULL
,	NULL
at	NULL
least	NULL
some	NULL
biologically	NULL
active	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
was	NULL
present	NULL
in	NULL
our	NULL
extracts	NULL
.	NULL

The	NULL
HK1O01/80	NULL
contains	NULL
the	NULL
octamer	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
which	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
tissue-specific	NULL
expression	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
(	NULL
Staudt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Landolfi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

It	NULL
has	NULL
,	NULL
however	NULL
,	NULL
been	NULL
shown	NULL
previously	NULL
that	NULL
the	NULL
factors	NULL
binding	NULL
in	NULL
this	NULL
region	NULL
are	NULL
found	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
cells	NULL
of	NULL
non-lymphoid	NULL
origin	NULL
in	NULL
addition	NULL
to	NULL
B	NULL
cells	NULL
(	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

As	NULL
in	NULL
our	NULL
study	NULL
,	NULL
the	NULL
complex	NULL
pattern	NULL
of	NULL
shift	NULL
bands	NULL
observed	NULL
by	NULL
Landolfi	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
,	NULL
which	NULL
was	NULL
thought	NULL
to	NULL
be	NULL
cell-type	NULL
or	NULL
stage-specific	NULL
may	NULL
,	NULL
in	NULL
fact	NULL
,	NULL
result	NULL
from	NULL
the	NULL
action	NULL
of	NULL
proteases	NULL
present	NULL
in	NULL
nuclear	NULL
extract	NULL
preparations	NULL
(	NULL
Mather	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

In	NULL
our	NULL
mobility	NULL
shift	NULL
assay	NULL
the	NULL
only	NULL
nuclear	NULL
extracts	NULL
which	NULL
were	NULL
active	NULL
in	NULL
causing	NULL
the	NULL
mobility	NULL
shift	NULL
of	NULL
HK101/2	NULL
were	NULL
these	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
plasmacytomas	NULL
.	NULL

None	NULL
of	NULL
the	NULL
other	NULL
extracts	NULL
(	NULL
including	NULL
the	NULL
large	NULL
non-cleaved	NULL
cell	NULL
and	NULL
Burkitt	NULL
's	NULL
lymphomas	NULL
)	NULL
,	NULL
which	NULL
caused	NULL
the	NULL
enhancement	NULL
of	NULL
in	NULL
vitro	NULL
transcription	NULL
of	NULL
HK1i01/3	NULL
clone	NULL
,	NULL
produced	NULL
any	NULL
shift	NULL
of	NULL
HK101/2	NULL
mobility	NULL
.	NULL

This	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
concentration	NULL
of	NULL
transacting	NULL
protein	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
in	NULL
different	NULL
nuclear	NULL
extracts	NULL
,	NULL
their	NULL
degradation	NULL
during	NULL
the	NULL
nuclear	NULL
extract	NULL
preparation	NULL
,	NULL
to	NULL
the	NULL
size	NULL
of	NULL
the	NULL
fragment	NULL
used	NULL
for	NULL
the	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
and	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
we	NULL
have	NULL
used	NULL
agarose	NULL
instead	NULL
of	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

It	NULL
is	NULL
of	NULL
notice	NULL
that	NULL
only	NULL
a	NULL
slight	NULL
shift	NULL
is	NULL
observed	NULL
in	NULL
our	NULL
assay	NULL
.	NULL

This	NULL
,	NULL
however	NULL
,	NULL
is	NULL
not	NULL
surprising	NULL
in	NULL
view	NULL
of	NULL
the	NULL
size	NULL
of	NULL
the	NULL
fragment	NULL
used	NULL
(	NULL
920	NULL
bp	NULL
)	NULL
.	NULL

Sequencing	NULL
and	NULL
subdividing	NULL
of	NULL
this	NULL
fragment	NULL
may	NULL
lead	NULL
to	NULL
the	NULL
discovery	NULL
of	NULL
novel	NULL
DNA	NULL
sequences	NULL
as	NULL
well	NULL
as	NULL
novel	NULL
protein	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
,	NULL
which	NULL
control	NULL
the	NULL
transcription	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
in	NULL
human	NULL
lymphoid	NULL
neoplasia	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Doctor	NULL
David	NULL
L.	NULL
Bentley	NULL
(	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
)	NULL
for	NULL
providing	NULL
the	NULL
HK	NULL
101/3	NULL
gene	NULL
,	NULL
and	NULL
Doctors	NULL
Hans	NULL
Messner	NULL
(	NULL
Ontario	NULL
Cancer	NULL
Institute	NULL
,	NULL
Toronto	NULL
)	NULL
and	NULL
Theodore	NULL
Zipf	NULL
(	NULL
University	NULL
of	NULL
Calgary	NULL
)	NULL
who	NULL
provided	NULL
the	NULL
human	NULL
lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Cathy	NULL
Hesch	NULL
and	NULL
Myrna	NULL
Hannon	NULL
for	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
Research	NULL
and	NULL
Development	NULL
Grant	NULL
provided	NULL
by	NULL
the	NULL
Foothills	NULL
Hospital	NULL
,	NULL
Calgary	NULL
,	NULL
Alberta	NULL
,	NULL
Canada	NULL
.	NULL

REFERENCES	NULL
ATCHISON	NULL
ML	NULL
.	NULL

&	NULL
Perry	NULL
R.P	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
The	NULL
role	NULL
of	NULL
the	NULL
x	NULL
enhancer	NULL
and	NULL
its	NULL
binding	NULL
factor	NULL
NF-	NULL
,	NULL
B	NULL
in	NULL
the	NULL
developmental	NULL
regulation	NULL
of	NULL
x	NULL
gene	NULL
transcription	NULL
.	NULL

Cell	NULL
,	NULL
48	NULL
,	NULL
121	NULL
.	NULL

AUGEREAU	NULL
P.	NULL
&	NULL
CHAMBON	NULL
P.	NULL
(	NULL
1986	NULL
)	NULL
The	NULL
mouse	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
:	NULL
effect	NULL
on	NULL
transcription	NULL
in	NULL
vitro	NULL
and	NULL
binding	NULL
of	NULL
proteins	NULL
present	NULL
in	NULL
HeLa	NULL
and	NULL
lymphoid	NULL
B	NULL
cell	NULL
extracts	NULL
.	NULL

Embo	NULL
J	NULL
.	NULL

5	NULL
,	NULL
1791	NULL
.	NULL

BazetT-Jones	NULL
D.P	NULL
.	NULL

,	NULL
Yecket	NULL
M.	NULL
&	NULL
GottesrELD	NULL
J.M	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Nuclear	NULL
extracts	NULL
from	NULL
globin-synthesizing	NULL
cells	NULL
enhance	NULL
globin	NULL
transcription	NULL
in	NULL
vitro	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
317	NULL
,	NULL
824	NULL
.	NULL

Bentuey	NULL
D.L	NULL
.	NULL

,	NULL
FarRELL	NULL
P.T	NULL
.	NULL

&	NULL
RaBBits	NULL
T.H	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Unrearranged	NULL
immunoglobulin	NULL
variable	NULL
region	NULL
genes	NULL
have	NULL
a	NULL
functional	NULL
promoter	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

10	NULL
,	NULL
1841	NULL
.	NULL

Bentcey	NULL
D.L	NULL
.	NULL

&	NULL
Rassits	NULL
T.H	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Human	NULL
V	NULL
,	NULL
immunoglobulin	NULL
gene	NULL
number	NULL
:	NULL
implications	NULL
for	NULL
the	NULL
origin	NULL
of	NULL
antibody	NULL
diversity	NULL
.	NULL

Cell	NULL
,	NULL
24	NULL
,	NULL
613	NULL
.	NULL

Dignam	NULL
J.D	NULL
.	NULL

,	NULL
Lesovitz	NULL
R.M	NULL
.	NULL

&	NULL
Roeper	NULL
RG	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475	NULL
.	NULL

Doven	NULL
N.	NULL
,	NULL
LEBLOND-FrRancitLarp	NULL
M.	NULL
,	NULL
Hom	NULL
I.	NULL
,	NULL
Drevrus	NULL
M.	NULL
&	NULL
RougEon	NULL
F.	NULL
(	NULL
1986	NULL
)	NULL
Analysis	NULL
of	NULL
promoter	NULL
and	NULL
enhancer	NULL
cell	NULL
type	NULL
specificities	NULL
and	NULL
the	NULL
regulation	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
.	NULL

Gene	NULL
,	NULL
50	NULL
,	NULL
321	NULL
.	NULL

EpHrUssi	NULL
A.	NULL
,	NULL
CHurck	NULL
G.M	NULL
.	NULL

,	NULL
TonEcawa	NULL
S.	NULL
&	NULL
Gicsert	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
B	NULL
lineage-specific	NULL
interactions	NULL
of	NULL
an	NULL
immunoglobulin	NULL
enhancer	NULL
with	NULL
cellular	NULL
factors	NULL
in	NULL
vivo	NULL
.	NULL

Science	NULL
,	NULL
227	NULL
,	NULL
134	NULL
.	NULL

FaALKNER	NULL
F.	NULL
G.	NULL
,	NULL
MociIKaT	NULL
R.	NULL
&	NULL
ZacHaw	NULL
H.G	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Sequences	NULL
closely	NULL
related	NULL
to	NULL
an	NULL
immunoglobulin	NULL
gene	NULL
promoter/enhancer	NULL
element	NULL
occur	NULL
also	NULL
upstream	NULL
of	NULL
other	NULL
eukaryotic	NULL
and	NULL
of	NULL
prokaryotic	NULL
genes	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

14	NULL
,	NULL
8819	NULL
.	NULL

FALKNER	NULL
F.G.	NULL
&	NULL
ZacHav	NULL
H.G	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Correct	NULL
transcription	NULL
of	NULL
an	NULL
immunoglobulin	NULL
,	NULL
gene	NULL
requires	NULL
an	NULL
upstream	NULL
fragment	NULL
containing	NULL
conserved	NULL
sequence	NULL
elements	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
310	NULL
,	NULL
71	NULL
.	NULL

Foon	NULL
K.A	NULL
.	NULL

,	NULL
SCHROFF	NULL
R.W	NULL
.	NULL

&	NULL
GaLe	NULL
R.P	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Surface	NULL
markers	NULL
on	NULL
leukemia	NULL
and	NULL
lymphoma	NULL
cells	NULL
:	NULL
recent	NULL
advances	NULL
.	NULL

Blood	NULL
,	NULL
60	NULL
,	NULL
1	NULL
.	NULL

GimBLE	NULL
J.M	NULL
.	NULL

,	NULL
Levens	NULL
D.	NULL
&	NULL
Max	NULL
E.E	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
B-cell	NULL
nuclear	NULL
proteins	NULL
binding	NULL
in	NULL
vitro	NULL
to	NULL
the	NULL
human	NULL
immunoglobulin	NULL
enhancer	NULL
:	NULL
localization	NULL
by	NULL
exonuclease	NULL
protection	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
1815	NULL
.	NULL

GopaAL	NULL
T.	NULL
&	NULL
FunpeRUD	NULL
S.	NULL
(	NULL
1982	NULL
)	NULL
.	NULL

Human	NULL
B-cell	NULL
neoplasms	NULL
in	NULL
relation	NULL
to	NULL
normal	NULL
B-cell	NULL
differentiation	NULL
and	NULL
maturation	NULL
processes	NULL
.	NULL

Adv	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

36	NULL
,	NULL
211	NULL
.	NULL

GoPaLt	NULL
T.V	NULL
.	NULL

,	NULL
SHimapa	NULL
T.	NULL
,	NULL
BaUr	NULL
A.W	NULL
.	NULL

&	NULL
NrenHuis	NULL
A.W	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Contribution	NULL
of	NULL
promoter	NULL
to	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
mouse	NULL
immunoglobulin	NULL
kappa	NULL
gene	NULL
.	NULL

Science	NULL
,	NULL
229	NULL
,	NULL
1102	NULL
.	NULL

Hromas	NULL
R.	NULL
&	NULL
Van	NULL
Ness	NULL
B	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Nuclear	NULL
factors	NULL
bind	NULL
to	NULL
regulatory	NULL
regions	NULL
of	NULL
the	NULL
mouse	NULL
kappa	NULL
immunoglobulin	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

14	NULL
,	NULL
4837	NULL
.	NULL

Kerrey	NULL
D.E	NULL
.	NULL

&	NULL
PerRY	NULL
R.P	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Transcriptional	NULL
and	NULL
post-transcrip-tional	NULL
control	NULL
of	NULL
immunoglobulin	NULL
mRNA	NULL
production	NULL
during	NULL
B	NULL
lymphocyte	NULL
development	NULL
.	NULL

Nucleic	NULL
Acid	NULL
Res	NULL
.	NULL

14	NULL
,	NULL
4531	NULL
.	NULL

Kossakowska	NULL
A.E	NULL
.	NULL

,	NULL
UrBanskI	NULL
S.J	NULL
.	NULL

,	NULL
TurF	NULL
A.J	NULL
.	NULL

&	NULL
Bazett-Jones	NULL
D.P	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Human	NULL
lymphoma	NULL
differentiation	NULL
concepts	NULL
correlate	NULL
with	NULL
in	NULL
vitro	NULL
action	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
specific	NULL
transcription	NULL
factors	NULL
.	NULL

Leukemia,2	NULL
,	NULL
290	NULL
.	NULL

Lamson	NULL
,	NULL
G.	NULL
&	NULL
KosHLanp	NULL
ME	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Changes	NULL
in	NULL
J	NULL
chain	NULL
and	NULL
p	NULL
chain	NULL
RNA	NULL
expression	NULL
as	NULL
a	NULL
function	NULL
of	NULL
B-cell	NULL
differentiation	NULL
.	NULL

J.	NULL
exp	NULL
.	NULL

Med	NULL
.	NULL

160	NULL
,	NULL
877	NULL
.	NULL

LANDOLFI	NULL
N.F	NULL
.	NULL

,	NULL
CaPRA	NULL
J.D	NULL
.	NULL

&	NULL
TuckER	NULL
P.W	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Interaction	NULL
of	NULL
cell-type-specific	NULL
nuclear	NULL
proteins	NULL
with	NULL
immunoglobulin	NULL
Vy	NULL
promoter	NULL
region	NULL
sequences	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
323	NULL
,	NULL
548	NULL
.	NULL

Lukes	NULL
R.J.	NULL
&	NULL
CoLLiNs	NULL
R.D	NULL
.	NULL

(	NULL
1974	NULL
)	NULL
Immunologic	NULL
characterization	NULL
of	NULL
human	NULL
malignant	NULL
lymphomas	NULL
.	NULL

Cancer	NULL
,	NULL
34	NULL
,	NULL
1488	NULL
.	NULL

Maney	NULL
J.L	NULL
.	NULL

,	NULL
FirE	NULL
A.	NULL
,	NULL
Cano	NULL
A.	NULL
,	NULL
SHARP	NULL
P.A	NULL
.	NULL

&	NULL
GertEr	NULL
M.L	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
DNA-dependent	NULL
transcription	NULL
of	NULL
adenovirus	NULL
genes	NULL
in	NULL
a	NULL
soluble	NULL
whole-cell	NULL
extract	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
77	NULL
,	NULL
3855	NULL
MatHER	NULL
EL	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
DNA-binding	NULL
factors	NULL
of	NULL
B	NULL
lymphoid	NULL
cells	NULL
are	NULL
susceptible	NULL
to	NULL
limited	NULL
proteolytic	NULL
cleavage	NULL
during	NULL
nuclear	NULL
extract	NULL
preparation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1812	NULL
.	NULL

MaTHER	NULL
EL	NULL
.	NULL

,	NULL
NELsoN	NULL
K.J	NULL
.	NULL

,	NULL
Haimovick	NULL
J	NULL
.	NULL

&	NULL
Perry	NULL
RP	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Mode	NULL
of	NULL
regulation	NULL
of	NULL
immunoglobulin	NULL
p-and-5	NULL
chain	NULL
expression	NULL
varies	NULL
during	NULL
B-lymphocyte	NULL
maturation	NULL
.	NULL

Cell	NULL
,	NULL
36	NULL
,	NULL
329	NULL
.	NULL

Mercota	NULL
M.	NULL
,	NULL
GOVERMAN	NULL
J.	NULL
,	NULL
MirELL	NULL
C.	NULL
&	NULL
CaLaMEe	NULL
K.	NULL
(	NULL
1985	NULL
)	NULL
Immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
requires	NULL
one	NULL
or	NULL
more	NULL
tissue-specific	NULL
factors	NULL
.	NULL

Science	NULL
,	NULL
227	NULL
,	NULL
266	NULL
.	NULL

J	NULL
.	NULL

&	NULL
Roeper	NULL
R.G	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Cell-type-specific	NULL
transcription	NULL
of	NULL
an	NULL
immunoglobulin	NULL
light	NULL
chain	NULL
gene	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
83	NULL
,	NULL
8511	NULL
.	NULL

MocikaT	NULL
R.	NULL
,	NULL
FALKNER	NULL
F.G.	NULL
,	NULL
MERTZ	NULL
R.	NULL
&	NULL
ZacHau	NULL
H.	NULL
(	NULL
1986	NULL
)	NULL
Upstream	NULL
regulatory	NULL
sequences	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
are	NULL
recognized	NULL
by	NULL
nuclear	NULL
proteins	NULL
which	NULL
also	NULL
bind	NULL
to	NULL
other	NULL
gene	NULL
regions	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

14	NULL
,	NULL
8829	NULL
.	NULL

Nirsson	NULL
K.	NULL
&	NULL
Krein	NULL
G.	NULL
(	NULL
1982	NULL
)	NULL
Phenotypic	NULL
and	NULL
cytogenetic	NULL
characteristics	NULL
of	NULL
human	NULL
B-lymphoid	NULL
cell	NULL
lines	NULL
and	NULL
their	NULL
relevance	NULL
for	NULL
the	NULL
etiology	NULL
of	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
.	NULL

Adv	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

37	NULL
,	NULL
319	NULL
.	NULL

334	NULL
A.	NULL
E.	NULL
Kossakowska	NULL
&	NULL
S.	NULL
J.	NULL
Urbanski	NULL
Posperov	NULL
V.A	NULL
.	NULL

,	NULL
KrosEck	NULL
H.G	NULL
.	NULL

&	NULL
Zackau	NULL
H.G	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Correlation	NULL
between	NULL
DNase	NULL
I	NULL
hypersensitive	NULL
sites	NULL
and	NULL
putative	NULL
regulatory	NULL
sequences	NULL
in	NULL
human	NULL
immunoglobulin	NULL
genes	NULL
of	NULL
the	NULL
x	NULL
light	NULL
chain	NULL
type	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

12	NULL
,	NULL
7007	NULL
.	NULL

ScHorer	NULL
H.R	NULL
.	NULL

&	NULL
Gruss	NULL
P.	NULL
(	NULL
1985	NULL
)	NULL
Cell	NULL
type-specific	NULL
transcriptional	NULL
enhancement	NULL
in	NULL
vitro	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
trans-acting	NULL
factors	NULL
.	NULL

Embo	NULL
J	NULL
.	NULL

4	NULL
,	NULL
3005	NULL
.	NULL

Sen	NULL
R.	NULL
&	NULL
Baltimore	NULL
D.	NULL
(	NULL
1986a	NULL
)	NULL
Inducibility	NULL
of	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF	NULL
-x	NULL
B	NULL
by	NULL
a	NULL
post-translational	NULL
mechanism	NULL
.	NULL

Cell	NULL
,	NULL
47	NULL
,	NULL
921	NULL
.	NULL

SEN	NULL
R.	NULL
&	NULL
BALTIMORE	NULL
D.	NULL
(	NULL
1986b	NULL
)	NULL
Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
sequences	NULL
.	NULL

Cell	NULL
,	NULL
46	NULL
,	NULL
705	NULL
.	NULL

STAUDT	NULL
L.M	NULL
.	NULL

,	NULL
Sinon	NULL
H.	NULL
,	NULL
SEN	NULL
R.	NULL
,	NULL
WirtH	NULL
T.	NULL
,	NULL
SHARP	NULL
P.A	NULL
.	NULL

&	NULL
BALTIMORE	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
A	NULL
lymphoid-specific	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
octamer	NULL
motif	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
323	NULL
,	NULL
640	NULL
.	NULL

WALL	NULL
R.	NULL
,	NULL
Briskin	NULL
M.	NULL
,	NULL
Carter	NULL
C.	NULL
,	NULL
GovaN	NULL
H.	NULL
,	NULL
TAYLOR	NULL
A	NULL
.	NULL

&	NULL
Kincape	NULL
P.	NULL
(	NULL
1986	NULL
)	NULL
A	NULL
labile	NULL
inhibitor	NULL
blocks	NULL
immunoglobulin	NULL
k-light-chain-gene	NULL
transcription	NULL
in	NULL
a	NULL
pre-B	NULL
leukemic	NULL
cell	NULL
line	NULL
.	NULL

Proc	NULL
.	NULL

natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
,	NULL
83	NULL
,	NULL
295	NULL
.	NULL

Wang	NULL
J.	NULL
,	NULL
NisHrvyama	NULL
K.	NULL
,	NULL
ARAKL	NULL
K.	NULL
,	NULL
Kitamura	NULL
D.	NULL
&	NULL
WaTANABE	NULL
T.	NULL
(	NULL
1987	NULL
)	NULL
Purification	NULL
of	NULL
an	NULL
octamer	NULL
sequence	NULL
(	NULL
ATGCAAAT	NULL
)	NULL
-binding	NULL
protein	NULL
from	NULL
human	NULL
B-cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15	NULL
,	NULL
10105	NULL
.	NULL

WEINBERGER	NULL
J.	NULL
,	NULL
BALTIMORE	NULL
D.	NULL
&	NULL
SHaRP	NULL
P.A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Distinct	NULL
factors	NULL
bind	NULL
to	NULL
apparently	NULL
homologous	NULL
sequences	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
322	NULL
,	NULL
846	NULL
.	NULL

WirtH	NULL
T.	NULL
,	NULL
STAUDT	NULL
L.	NULL
&	NULL
Baltimore	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
An	NULL
octamer	NULL
oligonucleo-tide	NULL
upstream	NULL
of	NULL
a	NULL
TATA	NULL
motif	NULL
is	NULL
sufficient	NULL
for	NULL
lymphoid-specific	NULL
promoter	NULL
activity	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
329	NULL
,	NULL
174	NULL
.	NULL

